Embecta (NASDAQ:EMBC - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.700-2.900 for the period, compared to the consensus estimate of 2.820. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Embecta Trading Down 9.8%
Shares of Embecta stock traded down $1.30 during trading on Friday, reaching $12.00. The stock had a trading volume of 975,119 shares, compared to its average volume of 447,584. The company has a market capitalization of $697.61 million, a price-to-earnings ratio of 12.00, a P/E/G ratio of 0.78 and a beta of 1.24. The stock has a fifty day moving average price of $12.45 and a two-hundred day moving average price of $15.76. Embecta has a 52 week low of $10.83 and a 52 week high of $21.48.
Embecta (NASDAQ:EMBC - Get Free Report) last released its earnings results on Friday, May 9th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.04. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. The business had revenue of $259.00 million during the quarter, compared to analysts' expectations of $261.77 million. During the same period last year, the business earned $0.67 earnings per share. The firm's revenue was down 9.8% on a year-over-year basis. On average, equities analysts forecast that Embecta will post 2.85 EPS for the current fiscal year.
Embecta Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Wednesday, May 28th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.00%. Embecta's dividend payout ratio (DPR) is currently 66.67%.
Wall Street Analyst Weigh In
Separately, Mizuho assumed coverage on Embecta in a research note on Thursday, April 10th. They set a "neutral" rating and a $15.00 target price on the stock.
Read Our Latest Stock Report on EMBC
Insider Buying and Selling
In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total transaction of $50,778.00. Following the transaction, the director now directly owns 36,133 shares in the company, valued at approximately $591,858.54. This represents a 7.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.42% of the stock is currently owned by insiders.
Embecta Company Profile
(
Get Free Report)
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Further Reading
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
